Statins for the Prevention of Dementia Among Older Male United States Veterans: A Target Trial Emulation

BACKGROUND AND OBJECTIVES: Several observational studies have reported a lower risk of dementia in statin users compared with nonusers, but these findings may be susceptible to bias. Whether statins prevent dementia would ideally be studied in a large, randomized trial that includes older adults followed for a long follow-up period. In the absence of such a trial, we can explicitly emulate a target trial of statins and risk of dementia using observational data. METHODS: Using electronic health records from the US Department of Veterans Affairs, we emulated a target trial of statin therapy and 10-year risk of dementia. Eligible individuals were men aged 60 years or older with no history of dementia, cardiovascular disease, chronic renal disease, diabetes, or statin use in the past year. The treatment strategies to be compared were initiation of any statin and continuation over follow-up (until the development of a contraindication or serious health condition) vs no statin initiation. The outcome of interest was diagnosis of any dementia. Risks were estimated through a pooled logistic regression model adjusted for baseline and time-varying covariates. RESULTS: A total of 81,599 statin initiators and 843,615 noninitiators were eligible for this study. The median age (interquartile range) was 64.3 years (61.2-70.3), and 11.7% were Black. The estimated 10-year dementia risks were 9.4% (95% CI 8.5-9.9) for statins and 9.6% (95% CI 8.9-10.3) for no statins. The corresponding risk difference was -0.2% (95% CI -0.9 to 0.4), and the risk ratio was 0.98 (95% CI 0.89-1.15). Estimates were similar within subgroups defined at baseline according to age, race, and frailty status based on deficit accumulation. CONCLUSION: Although the possibility of unmeasured confounding or misclassification cannot be entirely excluded, as in any observational study, this study involving a nationwide cohort of older male US veterans without prior cardiovascular disease suggests that statin therapy does not meaningfully influence dementia incidence over 10 years. CLASSIFICATION OF EVIDENCE: Per American Academy of Neurology Class of Evidence Classification, this study provides Class III evidence that statins do not reduce the incidence of dementia in men aged 60 years or older.

Authors

Institutions

Publication Details

Journal
Neurology
Published
2026-11-18
DOI
https://doi.org/10.1212/wnl.0000000000218765
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Statins for the Prevention of Dementia Among Older Male United States Veterans: A Target Trial Emulation

J. Michael Gaziano, Jessica K. Wise, Benjamin Viernes, Hanna Gerlovin et al.
Neurology
Dementia and Cognitive Impairment Research
article

Statins for the Prevention of Dementia Among Older Male United States Veterans: A Target Trial Emulation

J. Michael Gaziano, Jessica K. Wise, Benjamin Viernes, Hanna Gerlovin, Jacob Joseph, Alejandro Szmulewicz, Nicholas M. Pajewski, Ariela R. Orkaby, Karen P. Alexander, Barbra A. Dickerman, Michael J. Figueroa Muñiz, Walter T. Ambrosius, William Robb, Kelly Cho
article en

Abstract

BACKGROUND AND OBJECTIVES: Several observational studies have reported a lower risk of dementia in statin users compared with nonusers, but these findings may be susceptible to bias. Whether statins prevent dementia would ideally be studied in a large, randomized trial that includes older adults followed for a long follow-up period. In the absence of such a trial, we can explicitly emulate a target trial of statins and risk of dementia using observational data. METHODS: Using electronic health records from the US Department of Veterans Affairs, we emulated a target trial of statin therapy and 10-year risk of dementia. Eligible individuals were men aged 60 years or older with no history of dementia, cardiovascular disease, chronic renal disease, diabetes, or statin use in the past year. The treatment strategies to be compared were initiation of any statin and continuation over follow-up (until the development of a contraindication or serious health condition) vs no statin initiation. The outcome of interest was diagnosis of any dementia. Risks were estimated through a pooled logistic regression model adjusted for baseline and time-varying covariates. RESULTS: A total of 81,599 statin initiators and 843,615 noninitiators were eligible for this study. The median age (interquartile range) was 64.3 years (61.2-70.3), and 11.7% were Black. The estimated 10-year dementia risks were 9.4% (95% CI 8.5-9.9) for statins and 9.6% (95% CI 8.9-10.3) for no statins. The corresponding risk difference was -0.2% (95% CI -0.9 to 0.4), and the risk ratio was 0.98 (95% CI 0.89-1.15). Estimates were similar within subgroups defined at baseline according to age, race, and frailty status based on deficit accumulation. CONCLUSION: Although the possibility of unmeasured confounding or misclassification cannot be entirely excluded, as in any observational study, this study involving a nationwide cohort of older male US veterans without prior cardiovascular disease suggests that statin therapy does not meaningfully influence dementia incidence over 10 years. CLASSIFICATION OF EVIDENCE: Per American Academy of Neurology Class of Evidence Classification, this study provides Class III evidence that statins do not reduce the incidence of dementia in men aged 60 years or older.

NeurologyVol. 107(12)
Boston University (US), Brigham and Women's Hospital (US), Harvard University (US), Brown University (US), VA Boston Healthcare System (US), Providence VA Medical Center (US), VA Salt Lake City Healthcare System (US), Duke Medical Center (US), Wake Forest University Health Sciences (US), Duke Clinical Research Institute (US), New England Geriatric Research Education and Clinical Center (US), Wake Forest University (US)
Good health and well-being
Dementia and Cognitive Impairment Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon